Eli Lilly and Company (NYSE:LLY) Position Boosted by 180 Wealth Advisors LLC

180 Wealth Advisors LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 79.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,927 shares of the company’s stock after buying an additional 2,186 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $3,833,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $5,992,890,000. International Assets Investment Management LLC boosted its holdings in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after purchasing an additional 7,330,815 shares during the period. Sapient Capital LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $682,139,000. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares during the period. Finally, Comerica Bank acquired a new stake in shares of Eli Lilly and Company during the third quarter worth approximately $345,781,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $3.39 during trading hours on Friday, hitting $912.43. 647,346 shares of the company traded hands, compared to its average volume of 2,915,150. The stock has a market capitalization of $867.18 billion, a price-to-earnings ratio of 134.57, a P/E/G ratio of 1.97 and a beta of 0.36. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $915.54. The firm has a 50-day moving average of $807.55 and a 200 day moving average of $735.35. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.62 EPS. On average, analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 9,671 shares of the business’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $902.67, for a total value of $8,729,721.57. Following the sale, the insider now owns 97,574,139 shares of the company’s stock, valued at approximately $88,077,248,051.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 9,671 shares of the business’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $902.67, for a total value of $8,729,721.57. Following the sale, the insider now owns 97,574,139 shares of the company’s stock, valued at approximately $88,077,248,051.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares in the company, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders sold a total of 789,704 shares of company stock worth $672,385,964 in the last ninety days. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on LLY shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday. The Goldman Sachs Group raised their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Argus raised their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $812.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.